Clusterin Level and Polycystic Ovary Syndrome

Clusterin Level Determination and Its Association With Metabolic Syndrome in Patients With Polycystic Ovary Syndrome

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06601725

Enrollment

118

Registered

2024-09-19

Start date

2021-04-01

Completion date

2021-12-01

Last updated

2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovulation Disorder, Polycystic Ovary Syndrome

Keywords

clusterin, metabolic syndrome

Brief summary

Clusterin, a protein involved in metabolic syndrome, insulin resistance, and metabolic disorders associated with inflammation and oxidative stress such as atherosclerosis, Alzheimer's and some malignancies, has elevated levels in metabolic syndrome, PCOS, and the combination of these two groups. Clusterin could be used as an inflammatory marker to predict PCOS and metabolic syndrome.

Detailed description

The study included 118 women diagnosed with PCOS according to the Rotterdam criteria and 62 age-matched healthy women without cardiovascular risk factors. The patients diagnosed with PCOS were also classified into phenotypes. No interventional examination was requested for patients A, B, C, and D, except for hormonal tests and blood collection for Human Clusterin. The demographic and clinical characteristics of all patients were compared, with the primary outcome being blood Clusterin levels. The secondary outcomes are blood Clusterin levels in women with and without metabolic syndrome in addition to PCOS, the relationship between PCOS phenotypes and Clusterin levels, and the relationship between Clusterin levels and clinical and laboratory parameters.

Interventions

DIAGNOSTIC_TESTClusterin level

Clusterin plays a role in inflammation and oxidative stress processes such as metabolic syndrome, insulin resistance, and atherosclerosis

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

* Women aged between 18 and 45, * natural bilateral ovaries and no functional cysts on transvaginal ultrasound.

Exclusion criteria

* who have hyperandrogenism/hyperandrogenemia * who have non-classical congenital adrenal hyperplasia (17 OHP value \>2 nmol/L) * who have thyroid disease (TSH \>5 mlU/L), * women with hyperprolactinemia (Prolactin\>30 mlU/mL) * patients taking hormonal drugs or ovulation induction agents.

Design outcomes

Primary

Measure	Time frame	Description
CLusterin level	7 months	primary outcome is the measurement of blood Clusterin (Apolipoprotein J) levels in healthy women with and without PCOS

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026